All In Biotech

Drug Trial Radar · NCT03403205

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

A Phase 3, Randomized, Rater-Blinded, Multi-Center Study to Evaluate the Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older, With an Extension Period of up to 60 Months

Last checked: Nov 20, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 214 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

214

Actual

Start

Feb 22, 2018

Primary completion

Jun 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and safety will be evaluated during an optional 60-month Extension Period.

Conditions

  • Wilson Disease

Interventions

  • ALXN1840Drug

    ALXN1840 administered orally in 15 mg tablets

  • SoC TherapyDrug

    Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W)Time frame: Baseline to Week 48

Locations

56 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Chicago, Illinois

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Houston, Texas

  • Research Site

    Seattle, Washington

  • Research Site

    Adelaide, Australia

  • Research Site

    Concord, Australia

  • Research Site

    Parkville, Australia

  • Research Site

    Parkville, Australia

  • Research Site

    Graz, Austria

  • Research Site

    Innsbruck, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Prague, Czechia

  • Research Site

    Århus N, Denmark

  • Research Site

    Bron, France

  • Research Site

    Paris, France

  • Research Site

    Hamburg, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Leipzig, Germany

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Budapest, Hungary

  • Research Site

    Jerusalem, Israel

  • Research Site

    Ramat Gan, Israel

  • Research Site

    Chiba, Japan

  • Research Site

    Kumamoto, Japan

  • Research Site

    Kurume-shi, Japan

  • Research Site

    Matsuyama, Japan

  • Research Site

    Meguro-ku, Japan

  • Research Site

    Sapporo, Japan

  • Research Site

    Takatsuki-shi, Japan

  • Research Site

    Yokohama, Japan

  • Research Site

    Grafton, New Zealand

  • Research Site

    Warsaw, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.